Tonix Pharmaceuticals Holding Corp. SEC filings document a commercial-stage biotechnology company with Nasdaq-listed common stock and programs spanning CNS disorders, immunology, infectious diseases and rare diseases. Recent Form 8-K reports cover Regulation FD disclosures, selected operating and financial results, capital-structure information, commercial arrangements for TONMYA, and clinical or preclinical updates for programs such as TNX-4800, TNX-1700 and TNX-1900.
The company’s proxy and annual meeting filings describe board elections, shareholder voting results, equity incentive plan approvals, executive compensation matters and other governance subjects. Tonix filings also provide formal records of material events, exhibit-based press releases and presentations, risk-related disclosures, registered securities and public-company reporting obligations.
Tonix Pharmaceuticals Holding Corp. reporting persons Sirenia Capital Management and Alex Silverstein disclose beneficial ownership of 1,297,470 shares of common stock, representing 8.8% of the class on an as‑converted basis. The percentage "assumes the exercise of the warrants" held by the Sirenia Fund.
The filing cites 14,205,401 shares outstanding as of March 27, 2026 from the issuer's proxy statement and notes that 615,025 shares are issuable upon exercise of warrants included in the reported total.
Tonix Pharmaceuticals Holding Corp. director Richard Newcomb Stillwell received a stock option grant covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share and expire on May 12, 2036. They were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. After this compensation award, Stillwell holds 22,700 derivative securities linked to common stock directly, with no open-market purchase or sale reported in this filing.
Tonix Pharmaceuticals Holding Corp. director Adeoye Y Olukotun reported receiving a stock option grant covering 22,700 shares of common stock. The option has an exercise price of $13.28 per share and expires on May 12, 2036. It was granted under the company’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Following this grant, Olukotun holds stock options for 22,700 underlying shares directly.
Tonix Pharmaceuticals Holding Corp. director Margaret Smith Bell received a grant of stock options as part of equity compensation. She was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share. The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, she holds derivative rights to 22,700 shares through these options, which expire in 2036.
Tonix Pharmaceuticals Holding Corp. director Hunter James Randolph Jr reported receiving a grant of stock options as part of his compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share, with no cash paid at grant.
The options were granted under the company’s 2026 Stock Incentive Plan and vest on the earlier of one year from the grant date or the company’s 2027 Annual Meeting of Stockholders. Following this grant, Randolph holds options for 22,700 underlying shares directly.
Tonix Pharmaceuticals Holding Corp. director James Treco received a grant of stock options as part of equity compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share, expiring in 2036.
The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the May 12, 2026 grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, Treco holds options for 22,700 shares directly.
Tonix Pharmaceuticals Holding Corp. director David L. Grange received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share, vest on the earlier of one year from grant or the 2027 annual stockholders meeting, and expire in 2036.
Tonix Pharmaceuticals Holding Corp. director Richard H. Bagger received a grant of stock options as part of his compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share. These options were granted under the company’s 2026 Stock Incentive Plan and vest on the earlier of one year after the grant date or the 2027 Annual Meeting of Stockholders. Following this award, he holds 22,700 derivative securities directly.
Tonix Pharmaceuticals Holding Corp. reported that director Carolyn E. Taylor received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share and expire on May 12, 2036.
The award was granted under Tonix’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the May 12, 2026 grant date and the company’s 2027 Annual Meeting of Stockholders. Following this grant, Taylor holds stock options for 22,700 shares as reported in this filing.
Tonix Pharmaceuticals reported first quarter 2026 results showing early commercial traction for TONMYA alongside higher spending and losses. Net product revenue rose to approximately $6.9 million, up from $2.4 million a year earlier, driven by TONMYA, Zembrace SymTouch and Tosymra.
Net revenue from TONMYA was about $3.7 million in the quarter, with roughly 2,145 prescribers, 3,588 patients starting treatment and ~5,400 prescriptions filled in the first full quarter since launch. Research and development expenses increased to about $18.2 million and selling, general and administrative expenses to $28.6 million as the company invested in its pipeline and commercial infrastructure.
Tonix posted a net loss available to common stockholders of approximately $40.2 million, or $2.93 per share, compared with a loss of about $16.8 million, or $2.84 per share, in the prior-year quarter. Cash and cash equivalents were roughly $185.5 million as of March 31, 2026, and management believes existing cash plus second-quarter equity proceeds will fund operations into early second quarter 2027.